SMSbiotech has been developing cutting-edge adult stem cell technology that aims at providing safe, affordable, and ethically grounded regenerative medicine. We developed a patented technology (3 received, 10 pending) that can bio-manufacture human Small Mobile Stem Cells and proteins derived from these cells. These include matrisomal and other extracellular matrix proteins. Further development established large, industrial-scale production capability for the cells and their byproducts.
We have established proprietary techniques for the isolation and indefinite growth of native adult SMS cells. SMS cell bio-manufacturing quality is tested using novel, in vitro, functional assay systems ensuring in vivo potency at the cellular and molecular level. Consistent with their true stem cell characteristics, these cells have not been transformed or manipulated and are prime candidates for future use in clinical cell therapy and tissue engineering.
SMS cells have strong interactions with cells that are known to be key to cell and tissue regeneration (stem cells, progenitor cells, endothelial cells, and other cells) leading to growth stimulation and gene expression changes. They further produce large quantities of proteins that are known to have an important regenerative effect on various human cells and tissues. Extracellular matrix derived from SMS cells demonstrates strong blood vessel inducement in vitro and in vivo. SMS cells are resilient, withstanding physical and chemical stress, essentially made to serve tissues and organs under stressful diseased conditions. The resilience of SMS cells provides opportunities for drug administration/delivery and rational logistics.
SMS cells in vivo therapeutic potential have been studied in animal models. The cells exhibited exceptional abilities for regenerating damaged tissues in the skin and the lungs. The safety of these cells has been investigated using large numbers of these cells administered to animals in various tissues. No adverse effects were detected by applying these cells to multiple organs and multiple animal species. SMS cells were also rigorously and successfully tested on immunocompromised animals for the absence of tumorigenicity, as would be expected from an adult stem cell. (link to presentation)
Stimulation of parenchymal cells and stem cell proliferation, as well as tissue vascularization and the production of extracellular matrix, are critical processes that are fundamental and essential for the rapid and effective healing of damaged tissues in most if not all organs.
Chronic Obstructive Pulmonary Disease (COPD), an example of progressive, degenerative lung disease, is the third leading cause of death worldwide. Currently, there is no cure or effective treatment for this disease. SMSbiotech’s leading in vitro and in vivo research demonstrates that this disease is a prime target for SMS cells and their regenerative effect.
Our technology will provide patients with access to high-quality, immuno-tolerant, and affordable human (allogeneic) therapeutic cells. In addition, these cells will provide other therapeutic byproducts, such as critical therapeutic proteins at an industrial scale. This robust technology will enable the high-volume and reproducible production of human medical-grade cells and proteins such as ECMs. Both of these are crucial components of in vivo tissue regeneration and in vitro tissue reconstruction. Our technology will help facilitate the development of cost-effective methods for (1) organ repair, (2) tissue and vascular regeneration, and (3) scaffold and tissue engineering.
Why SMS Cells Are Superior To Other Stem Cells
∙ In contrast to embryonic and genetically engineered cells, Small Mobile Stem (SMS) cells are adult stem cells originating from adult human tissues. Transferring SMS cells to human tissue does not expose adult tissue to embryonic state cells. Furthermore, SMS cells are not genetically manipulated cells.
∙ Adult stem cells, mainly Mesenchymal stem cells, have been gaining a lot of momentum in cell therapy. SMS cells however post significant and crucial advantages over Mesenchymal stem cells.
∙ Unlike adult Mesenchymal Stem cells, SMS cells are isolated from regular blood. Injecting SMS cells into the bloodstream returns them back to their “natural habitat”. SMS cells have very few to no histocompatibility proteins, meaning they are unlikely to induce a significant immune-reaction.
∙ Unlike Mesenchymal stem cells that target mainly the immune cells, SMS cells target several different cells that have direct significance to tissue regeneration.
∙ SMS cells stimulate mesenchymal stem cell proliferation and may therefore induce the beneficial regenerative effects of MSC, endogenously.
∙ SMS cells are sturdier, more robust, and easier to handle. SMS cells are much smaller and, unlike the Mesenchymal cells, will unlikely clog capillaries and get stuck in the lungs.
∙ SMS cells have the ability to proliferate extensively without the loss of functional potency. They retain the ability to differentiate into other cells, interact with key regenerative cells, and produce important regenerative factors.
∙ SMS cells have been proliferated extensively more than MSCs and then tested in vitro and in vivo, using multiple animal species, for consistent safety and absence of toxicity and tumorigenicity.